Novel treatment avenues for peripheral T-cell lymphomas

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Peripheral T-cell lymphomas (PTCLs) and natural killer (NK) or T-cell non-Hodgkin's lymphomas (NHLs) are rare, heterogeneous cancers with poor prognoses.
• The World Health Organization (WHO) recognizes 18 distinct subtypes of PTCL and NK T-cell lymphomas.

Purpose of the Study:

• To provide a concise overview of the clinical diagnosis, current treatment options, and emerging therapeutic strategies for PTCLs and NHLs.
• To highlight the need for novel treatment approaches due to the limitations of current therapies.

Main Methods:

• Diagnosis relies on histology, flow cytometry, cytogenetics, fluorescence in situ hybridization (FISH), and T-cell receptor (TCR) rearrangement analysis.
• Staging and follow-up utilize imaging techniques like computed tomography (CT) and positron emission tomography (PET).
• The review discusses targeted substances including antimetabolites, antibodies, histone deacetylase inhibitors, tyrosine kinase inhibitors, and immunomodulatory drugs like lenalidomide.

Main Results:

• Current standard chemotherapy regimens (e.g., CHOP) achieve response rates of 60-70% but yield only approximately 30% 5-year survival.
• Novel therapeutic approaches targeting tumor cells directly are under investigation.

Conclusions:

• Future advancements in deep sequencing and interdisciplinary collaboration (geneticists, biochemists, clinicians) will refine treatment strategies.
• Personalized medicine approaches tailored to individual patient needs are anticipated to improve outcomes for PTCLs and NHLs.